FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385405962> ?p ?o ?g. }

• W4385405962 endingPage "911" @default.
• W4385405962 startingPage "911" @default.
• W4385405962 abstract "The recombinant COVID-19 vaccine NVX-CoV2373 has demonstrated efficacy of approximately 90% in adults; however, its safety and efficacy in children is unknown.To assess the noninferiority of SII-NVX-CoV2373 in children and adolescents compared to adults and to evaluate its safety in comparison with placebo.This phase 2-3 observer-blind randomized clinical trial was conducted in 2 cohorts, children (aged 2 to 11 years) and adolescents (aged 12 to 17 years) between August 2021 and August 2022. Participants were randomized 3:1 to SII-NVX-CoV2373 or placebo and monitored for 179 days. The participants, study team, and laboratory staff were blinded. This was a multicenter study conducted across 10 tertiary care hospitals in India. Exclusion criteria included previous COVID-19 infection or vaccination, immunocompromised condition, and immunosuppressive medications.Two doses of 0.5-mL SII-NVX-CoV2373 or placebo were administered intramuscularly on days 1 and 22.Primary outcomes were geometric mean titer ratio of both anti-spike (anti-S) IgG and neutralizing antibodies (NAbs) between both pediatric age groups to that of adults on day 36. Noninferiority was concluded if the lower bound of 95% CI of this ratio was greater than 0.67 for each age group. Both the antibodies were assessed for the index strain and for selected variants at various time points. Solicited adverse events (AEs) were recorded for 7 days after each vaccination, unsolicited AEs were recorded for 35 days, and serious AEs and AEs of special interest were recorded for 179 days.A total of 460 children in each age cohort were randomized to receive vaccine or placebo. The mean (SD) age was 6.7 (2.7) years in the child cohort and 14.3 (1.6) years in the adolescent cohort; 231 participants (50.2%) in the child cohort and 218 in the adolescent cohort (47.4%) were female. Both anti-S IgG and NAb titers were markedly higher in the SII-NVX-CoV2373 group than in the placebo group on both day 36 and day 180. The geometric mean titer ratios compared to those in adults were 1.20 (95% CI, 1.08-1.34) and 1.52 (95% CI, 1.38-1.67) for anti-S IgG in adolescents and children, respectively; while for NAbs, they were 1.33 (95% CI, 1.17-1.50) and 1.93 (95% CI, 1.70-2.18) in adolescents and children, respectively, indicating noninferiority. SII-NVX-CoV2373 also showed immune responses against variants studied. Injection site reactions, fever, headache, malaise, and fatigue were common solicited AEs. There were no AEs of special interest and no causally related serious AEs.SII-NVX-CoV2373 was safe and well tolerated in children and adolescents in this study. The vaccine was highly immunogenic and may be used in pediatric vaccination against COVID-19.Clinical Trials Registry of India Identifier: CTRI/2021/02/031554." @default.
• W4385405962 created "2023-08-01" @default.
• W4385405962 creator A5001744755 @default.
• W4385405962 creator A5003158887 @default.
• W4385405962 creator A5006042494 @default.
• W4385405962 creator A5006103504 @default.
• W4385405962 creator A5006914237 @default.
• W4385405962 creator A5007113312 @default.
• W4385405962 creator A5008674115 @default.
• W4385405962 creator A5008896575 @default.
• W4385405962 creator A5008969249 @default.
• W4385405962 creator A5010086755 @default.
• W4385405962 creator A5010434226 @default.
• W4385405962 creator A5013185196 @default.
• W4385405962 creator A5017931794 @default.
• W4385405962 creator A5018868625 @default.
• W4385405962 creator A5019137894 @default.
• W4385405962 creator A5022414853 @default.
• W4385405962 creator A5022822516 @default.
• W4385405962 creator A5023414888 @default.
• W4385405962 creator A5024910650 @default.
• W4385405962 creator A5029404552 @default.
• W4385405962 creator A5030082102 @default.
• W4385405962 creator A5032295889 @default.
• W4385405962 creator A5035575209 @default.
• W4385405962 creator A5036164794 @default.
• W4385405962 creator A5038869214 @default.
• W4385405962 creator A5040793682 @default.
• W4385405962 creator A5042159661 @default.
• W4385405962 creator A5042324494 @default.
• W4385405962 creator A5044182110 @default.
• W4385405962 creator A5045948382 @default.
• W4385405962 creator A5047138862 @default.
• W4385405962 creator A5052078528 @default.
• W4385405962 creator A5055179202 @default.
• W4385405962 creator A5056415697 @default.
• W4385405962 creator A5056788113 @default.
• W4385405962 creator A5058844147 @default.
• W4385405962 creator A5059260426 @default.
• W4385405962 creator A5059563278 @default.
• W4385405962 creator A5064452626 @default.
• W4385405962 creator A5066948741 @default.
• W4385405962 creator A5067777800 @default.
• W4385405962 creator A5068620258 @default.
• W4385405962 creator A5072784089 @default.
• W4385405962 creator A5073365304 @default.
• W4385405962 creator A5076130506 @default.
• W4385405962 creator A5076192745 @default.
• W4385405962 creator A5080084921 @default.
• W4385405962 creator A5081746974 @default.
• W4385405962 creator A5084195952 @default.
• W4385405962 creator A5084767961 @default.
• W4385405962 creator A5091520026 @default.
• W4385405962 creator A5092572999 @default.
• W4385405962 date "2023-09-01" @default.
• W4385405962 modified "2023-09-27" @default.
• W4385405962 title "Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India" @default.
• W4385405962 cites W2100358124 @default.
• W4385405962 cites W2109471081 @default.
• W4385405962 cites W3034304416 @default.
• W4385405962 cites W3082729388 @default.
• W4385405962 cites W3124577871 @default.
• W4385405962 cites W3135617626 @default.
• W4385405962 cites W3164720238 @default.
• W4385405962 cites W3174017401 @default.
• W4385405962 cites W3187766579 @default.
• W4385405962 cites W3189960399 @default.
• W4385405962 cites W3190825968 @default.
• W4385405962 cites W3194784134 @default.
• W4385405962 cites W3199097280 @default.
• W4385405962 cites W3200588773 @default.
• W4385405962 cites W3207125349 @default.
• W4385405962 cites W3212053680 @default.
• W4385405962 cites W4200280110 @default.
• W4385405962 cites W4200329071 @default.
• W4385405962 cites W4200408597 @default.
• W4385405962 cites W4205682741 @default.
• W4385405962 cites W4206888452 @default.
• W4385405962 cites W4207040364 @default.
• W4385405962 cites W4210835826 @default.
• W4385405962 cites W4211200665 @default.
• W4385405962 cites W4220734224 @default.
• W4385405962 cites W4220793636 @default.
• W4385405962 cites W4225612109 @default.
• W4385405962 cites W4226312482 @default.
• W4385405962 cites W4229445171 @default.
• W4385405962 cites W4245542824 @default.
• W4385405962 cites W4280546528 @default.
• W4385405962 cites W4280607167 @default.
• W4385405962 cites W4283033055 @default.
• W4385405962 cites W4283749887 @default.
• W4385405962 cites W4283769971 @default.
• W4385405962 cites W4285247093 @default.
• W4385405962 cites W4285719527 @default.
• W4385405962 cites W4288441808 @default.
• W4385405962 cites W4288746656 @default.
• W4385405962 cites W4289780066 @default.
• W4385405962 cites W4306839895 @default.

• next